Lv12
100 积分 2022-04-12 加入
The U.S. Food and Drug Administration’s Perspective on Chimeric Antigen Receptor T-Cell Therapies for Autoimmune and Rheumatic Conditions
17小时前
已完结
Discussion of Perspectives on Various Innovative Statistical Methodologies for Alzheimer’s Disease Clinical Trials
1个月前
已完结
Advancing CAR T-Cell Therapy
1个月前
已完结
Mitigating Limited Data Challenges to Improve Artificial Intelligence Integration in Rare Disease Drug Development
2个月前
已完结
FDA/CDER/OND Experience With New Approach Methodologies (NAMs)
2个月前
已完结
Mitigating Limited Data Challenges to Improve Artificial Intelligence Integration in Rare Disease Drug Development
2个月前
已关闭
Trends in FDA Data Integrity Enforcement Before and After the COVID-19 Pandemic: An Analysis of 1766 Warning Letters (2016–2023)
3个月前
已完结
EXPRESS: Are All Generic Drugs Created Equal? An Empirical Analysis of Generic Drug Manufacturing Location and Serious Drug Adverse Events
5个月前
已完结
Model-based approach for two-stage group sequential or adaptive designs in bioequivalence studies using parallel and crossover designs
6个月前
已完结
Isotretinoin Risk Evaluation and Mitigation Strategy and Pregnancy Incidence
6个月前
已完结
皖公网安备34019202002308
